| 6.365 -0.405 (-5.98%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.98  |
1-year : | 8.38 |
| Resists | First : | 5.98 |
Second : | 7.17 |
| Pivot price | 4.87  |
|||
| Supports | First : | 4.04 | Second : | 3.36 |
| MAs | MA(5) : | 4.97 |
MA(20) : | 4.85 |
| MA(100) : | 8.87 |
MA(250) : | 58.55 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 64.8 |
D(3) : | 62.5 |
| RSI | RSI(14): 43.8 |
|||
| 52-week | High : | 597.59 | Low : | 0.31 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ CYCC ] has closed below upper band by 20.7%. Bollinger Bands are 94.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 50 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.59 - 5.63 | 5.63 - 5.66 |
| Low: | 4.49 - 4.52 | 4.52 - 4.55 |
| Close: | 5.08 - 5.14 | 5.14 - 5.18 |
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.
Fri, 05 Sep 2025
Cyclacel Pharmaceuticals shareholders approve share issuance and name change - Investing.com
Mon, 04 Aug 2025
Cyclacel Pharmaceuticals Highlights Promising Preclinical Study on Plogosertib for Treating Biliary Tract Cancer - Quiver Quantitative
Wed, 16 Jul 2025
CYCLACEL PHARMACEUTICALS COMMENTS ON RECENT STOCK PRICE VOLATILITY - Yahoo Finance
Tue, 15 Jul 2025
Pre-market Movers: KAPA, CYCC, SONN, RANI... - RTTNews
Tue, 15 Jul 2025
Cyclacel Pharmaceuticals Stock Soars: Investing or Waiting? - timothysykes.com
Tue, 15 Jul 2025
Why Is Cyclacel Pharmaceuticals Stock Soaring On Tuesday? - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | -9 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | 2.24e+006 (%) |
| Held by Institutions | 14640 (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.036e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 123.5 |
| Profit Margin | 0 % |
| Operating Margin | -103 % |
| Return on Assets (ttm) | 580 % |
| Return on Equity (ttm) | -102.9 % |
| Qtrly Rev. Growth | 10000 % |
| Gross Profit (p.s.) | -188.68 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 81132.1 |
| Qtrly Earnings Growth | 7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0.04 |
| Price to Sales | 0 |
| Price to Cash Flow | 0 |
| Dividend | 96280 |
| Forward Dividend | 101020 |
| Dividend Yield | 1876800% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|